Compare Natera Inc. Common Stock (NTRA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Uranium Energy Corp — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Uranium Energy Corp trades at $7.7 (market cap $4.08B). The key difference: Natera Inc. Common Stock is far larger — about 14× Uranium Energy Corp's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Uranium Energy Corp for 38 Days on average.
| NTRA | UEC | |
|---|---|---|
Market Cap | $57.03B | $4.08B |
Volume | 1,131,157 | 14,920,249 |
Sector | Health | Energy |
52-Week High | $425.64 | $20.14 |
52-Week Low | $179.42 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $56.18B | $3.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Uranium Energy (UEC) trades at $8.25, down 6.57% today, amid bearish technical signals despite strong analyst support. The company shows operational improvements with multi-mine expansion but faces fundamental challenges with negative net income margins (-368.62%) and declining revenue from $67M in 2025 to $37M in 2026. Recent Q4 2026 earnings beat revenue estimates but missed on EPS, while technical indicators show 18 sell signals versus 3 buy signals.
The stock presents a high-risk opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting with weak financials. Key risks include unsustainable production growth, dependence on inventory sales, and cash flow challenges. Upside depends on successful execution of uranium production ramp-up and favorable government demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
